Bal Pharma Ltd.
₹107.70
+1.40%
Delayed · cached 15 min
Fair value analysis
BALPHARMA
Bal Pharma Ltd.
₹106.21
Close used for this calculation
₹148.20Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
51/100
Quality radar
Consensus fair value
₹148.20
Below FV▲ +39.5% against the close used
Model range ₹27.28 – ₹381.36
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹27.28Fair value₹148.20Bull₹381.36
FairClose
52-week traded range
52W low ₹60.4252W high ₹114.45
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
Bal Pharma Ltd. closed at ₹106.21, 28.3% below the consensus fair value of ₹148.20 drawn from 10 valuation models.
Financial DNA score 51/100 — Good. P/E of 23.8x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹98.63
-7.1%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹71.93
-32.3%
√(22.5 × EPS × BVPS)
EPS=3.94, BVPS=58.36 · outside Graham range (P/E 23.8, P/B 1.8) — asset-light, treat as a rough floor
Graham Formula
₹177.44
+67.1%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=20%, FD=7%
P/E Fair Value
₹140.66
+32.4%
EPS × 35.7x (sector P/E)
EPS=3.94, Sector P/E=35.7x
Peter Lynch (PEG)
₹98.50
-7.3%
EPS × Growth% (PEG = 1 is fair)
EPS=3.94, g=25%
EV/EBITDA
₹381.36
+259.1%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=430M
Dividend Discount (DDM)
₹64.24
-39.5%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=1.19, r=10%, g=8%
Book Value (P/B)
₹27.28
-74.3%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=58.36, ROE=7.9%, g=6%, r=10%
Reverse DCF
₹106.21
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 11.2% | Historical: 25%
Margin of Safety
₹91.62
-13.7%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=122.16, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.